Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

11beta-Hydroxysteroid dehydrogenase inhibitor improves metabolic syndrome features

April 13, 2004

Phase II trial of FM-VP4 meets primary endpoint

April 8, 2004

Hypolipidemic effects of GW-707 occur via disruption of intracellular sterol trafficking

April 8, 2004

Germany approves ezetimibe/simvastatin for hypercholesterolemia

April 7, 2004

New DPP-IV inhibitors prepared and tested by Eisai researchers

April 7, 2004

Dual PPARalpha/gamma agonist effective against metabolic syndrome in vivo

April 7, 2004

Long-term effects of Diamyd in patients with autoimmune diabetes

April 7, 2004

Livial evaluated for sexual dysfunction

April 6, 2004

PDE4 inhibitors from Glenmark

April 5, 2004

Potassium channel blockers emerge from ICAgen research

April 5, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.